Earlier this week, The New England Journal of Medicine published the first results of the Pragmatic Nordic-European Initiative on Colorectal Cancer (NordICC) Trial of Colonoscopy, which was conducted in Poland, Norway, Sweden, and the Netherlands to measure the efficacy of colonoscopy in reducing colorectal cancer incidence and mortality.
Guardant Health Inc., a precision oncology company, announced that FDA has approved the company’s Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease.
